NewLink/Merck Ebola vaccine 'ring' study starts in Guinea
This article was originally published in Scrip
Executive Summary
A Phase III trial testing an experimental recombinant vesicular stomatitis virus (rVSV) Ebola vaccine from NewLink Genetics and its partner Merck using a "ring" vaccination strategy got underway this week in Coyah prefecture, Guinea, the World Health Organization (WHO), which is sponsoring the study, said on 25 March.